Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

PHASE4CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions
SchizophreniaSchizoaffective DisorderBipolar DisorderMajor Depressive DisorderTardive Dyskinesia
Interventions
DRUG

Valbenazine

Valbenazine capsules for oral administration

Trial Locations (27)

11004

Neurocrine Clinical Site, Glen Oaks

30060

Neurocrine Clinical Site, Marietta

30328

Neurocrine Clinical Site, Atlanta

32086

Neurocrine Clinical Site, Saint Augustine

32803

Neurocrine Clinical Site, Orlando

33016

Neurocrine Clinical Site, Miami Lakes

33176

Neurocrine Clinical Site, Miami

33629

Neurocrine Clinical Site, Tampa

34134

Neurocrine Clinical Site, Bonita Springs

34972

Neurocrine Clinical Site, Okeechobee

44122

Neurocrine Clinical Site, Beechwood

46601

Neurocrine Clinical Site, South Bend

60563

Neurocrine Clinical Site, Naperville

68526

Neurocrine Clinical Site, Lincoln

72022

Neurocrine Clinical Site, Bryant

73112

Neurocrine Clinical Site, Oklahoma City

75115

Neurocrine Clinical Site, DeSoto

77030

Neurocrine Clinical Site, Houston

77089

Neurocrine Clinical Site, Houston

79902

Neurocrine Clinical Site, El Paso

85351

Neurocrine Clinical Site, Sun City

90504

Neurocrine Clinical Site, Torrance

92103

Neurocrine Clinical Site, San Diego

92805

Neurocrine Clinical Site, Anaheim

92868

Neurocrine Clinical Site, Orange

95124

Neurocrine Clinical Site, San Jose

02747

Neurocrine Clinical Site, North Dartmouth

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY